etoposide has been researched along with nelarabine in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 6 (85.71) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Commander, LA; Insogna, IG; Rheingold, SR; Seif, AE | 1 |
Escherich, G; Hagel, C; Hartz, B; Löbel, U | 1 |
Frey, NV; Ganetsky, A; Landsburg, DJ; Loren, AW; Luger, SM; Luskin, MR; Nasta, SD; Porter, DL; Svoboda, J | 1 |
Bleckmann, K; Borkhardt, A; Bronsema, A; Burkhardt, B; Chen-Santel, C; Debatin, KM; Ebinger, M; Eckert, C; Escherich, G; Klingebiel, T; Kolb, R; Koscielniak, E; Kuhlen, M; Möricke, A; Queudeville, M; Rossig, C; Schrappe, M; Vieth, S; von Stackelberg, A; Vonalt, A; Zwaan, CM | 1 |
1 review(s) available for etoposide and nelarabine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for etoposide and nelarabine
Article | Year |
---|---|
Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Nervous System Diseases; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome; Young Adult | 2010 |
Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Male; Neurotoxicity Syndromes; Retrospective Studies; T-Lymphocytes | 2017 |
4 other study(ies) available for etoposide and nelarabine
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia.
Topics: Antimetabolites, Antineoplastic; Arabinonucleosides; Cerebellum; Child; Cyclophosphamide; Cytarabine; Etoposide; Fatal Outcome; Guillain-Barre Syndrome; Humans; Magnetic Resonance Imaging; Male; Medulla Oblongata; Methotrexate; Necrosis; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Seizures; Spinal Cord | 2013 |
Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy | 2016 |